Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.67 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.67 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.58 |
| ▸ | NSD3 | Q9BZ95 | 7/20 | 0.57 |
| ▸ | NSD2 | O96028 | 6/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA4 | P22748 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4364344 | 0.83 | ADORA2A (0.70) | FGFR1SLC22A6ADORA2AADORA1ADORA2B | |
| SCHEMBL382916 | 0.83 | FGFR1 (0.66) | FGFR1SLC22A6ADORA2AADORA1ADORA2B | |
| SCHEMBL2023978 | 0.83 | FGFR1 (0.70) | FGFR1SLC22A6ADORA2AADORA1ADORA2B | |
| SCHEMBL2032130 | 0.83 | FGFR1 (0.62) | FGFR1SLC22A6ADORA2AADORA1ADORA2B | |
| SCHEMBL97602 | 0.82 | FGFR1 (0.65) | FGFR1SLC22A6ADORA2AADORA1ADORA2B | |
| SCHEMBL1920123 | 0.82 | FGFR1 (0.65) | FGFR1SLC22A6ADORA2AADORA1ADORA2B | |
| Adefovir SCHEMBL29365535 | 0.80 | FGFR1 (1.00) | FGFR1SLC22A6ADORA2AADORA1ADORA2B | |
| SCHEMBL13114340 | 0.80 | FGFR1 (0.77) | FGFR1SLC22A6ADORA2AADORA1ADORA2B | |
| Adefovir SCHEMBL49373 | 0.80 | FGFR1 (1.00) | FGFR1SLC22A6ADORA2AADORA1ADORA2B | |
| SCHEMBL3304318 | 0.80 | FGFR1 (0.66) | FGFR1SLC22A6ADORA2AADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2326953-B1 | ADP DETECTION BASED LUMINESCENT PHOSPHOTRANSFERASE OR ATP HYDROLASE ASSAY | PROMEGA CORP (US) | 2018-03-21 | — | — | EP | disclosed |
| US-20170239279-A1 | PHOSPHONATE COMPOUNDS | UNIV CALIFORNIA (US) | 2017-08-24 | — | — | US | disclosed |
| WO-2017083304-A1 | THERAPEUTIC COMPOSITIONS FOR TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | GILEAD SCIENCES, INC. (US) | 2017-05-18 | — | — | WO | disclosed |
| US-9649321-B2 | Phosphonate compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-05-16 | — | — | US | disclosed |
| EP-2682397-B1 | Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same | GILEAD SCIENCES INC (US) | 2017-04-19 | — | — | EP | disclosed |
| US-8802411-B2 | ADP detection based luminescent phosphotransferase or ATP hydrolase assay | PROMEGA CORPORATION (US) | 2014-08-12 | — | — | US | disclosed |
| EP-1914237-B1 | Phosphonate ester antiviral compounds | UNIV CALIFORNIA (US) | 2014-06-18 | — | — | EP | disclosed |
| US-20120258480-A1 | ADP DETECTION BASED LUMINESCENT PHOSPHOTRANSFERASE OR ATP HYDROLASE ASSAY | PROMEGA CORPORATION (US) | 2012-10-11 | — | — | US | disclosed |
| US-8183007-B2 | ADP detection based methods using adenylate cyclase and bioluminescence | PROMEGA CORPORATION (US) | 2012-05-22 | — | — | US | disclosed |
| WO-2011075747-A1 | THERAPEUTIC COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-06-23 | — | — | WO | disclosed |
| EP-2326953-A1 | ADP DETECTION BASED LUMINESCENT PHOSPHOTRANSFERASE OR ATP HYDROLASE ASSAY | Promega Corporation (US) | 2011-06-01 | — | — | EP | disclosed |
| US-20100075350-A1 | ADP detection based luminescent phosphotransferase or ATP hydrolase assay | PROMEGA CORPORATION (US) | 2010-03-25 | — | — | US | disclosed |
| WO-2010011607-A1 | ADP DETECTION BASED LUMINESCENT PHOSPHOTRANSFERASE OR ATP HYDROLASE ASSAY | PROMEGA CORPORATION (US) | 2010-01-28 | — | — | WO | disclosed |
| CN-1850831-A | Method for preparing 9-(diethoxy phosphoryl methoxy ethyl)-adenine | UNIV HUADONG TECHNOLOGY (CN) | 2006-10-25 | — | — | CN | disclosed |
| US-6759238-B1 | POSSESSES BOTH DIAGNOSTIC AND THERAPEUTIC UTILITY AS DIAGNOSTIC KITS, INCLUDING DRUG ASSAYS AND SCREENS AS WELL AS PHARMACEUTICAL COMPOSITIONS AND THE CORRESPONDING METHODS OF THEIR RESPECTIVE USE | ST. JUDE CHILDREN'S RESEARCH HOSPITAL | 2004-07-06 | — | — | US | disclosed |
| WO-2000058471-A2 | MULTIDRUG RESISTANCE ASSOCIATED PROTEINS AND USES THEREOF | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170239279-A1 | PHOSPHONATE COMPOUNDS | PHPT1, PHOSPHO1, PIK3CA | FGFR1 1716/4885SLC22A6 903/4885ADORA2A 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.